Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteosarcoma | 41 | 2024 | 910 | 7.460 |
Why?
|
Bone Neoplasms | 51 | 2025 | 2563 | 5.660 |
Why?
|
Gastrointestinal Stromal Tumors | 16 | 2021 | 616 | 2.690 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 4 | 2023 | 43 | 1.990 |
Why?
|
Gastrointestinal Neoplasms | 8 | 2021 | 957 | 1.210 |
Why?
|
Neoplasms | 30 | 2024 | 22350 | 1.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 9 | 2024 | 3667 | 1.110 |
Why?
|
Succinate Dehydrogenase | 6 | 2016 | 148 | 1.110 |
Why?
|
Child | 106 | 2025 | 80771 | 0.990 |
Why?
|
Sarcoma | 10 | 2024 | 1802 | 0.940 |
Why?
|
Neoplasm Recurrence, Local | 22 | 2024 | 9410 | 0.910 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2022 | 2428 | 0.890 |
Why?
|
Molecular Targeted Therapy | 13 | 2024 | 2824 | 0.890 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2016 | 638 | 0.870 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 6 | 2019 | 367 | 0.840 |
Why?
|
Fibromatosis, Aggressive | 3 | 2020 | 125 | 0.820 |
Why?
|
Oncogene Proteins, Fusion | 8 | 2023 | 1608 | 0.750 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2021 | 68 | 0.740 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11872 | 0.710 |
Why?
|
Medical Oncology | 9 | 2023 | 2341 | 0.710 |
Why?
|
Proto-Oncogene Proteins c-kit | 7 | 2019 | 723 | 0.700 |
Why?
|
Ketones | 2 | 2018 | 183 | 0.690 |
Why?
|
Furans | 2 | 2018 | 199 | 0.680 |
Why?
|
Antineoplastic Agents | 12 | 2020 | 13650 | 0.680 |
Why?
|
Adolescent | 70 | 2024 | 89046 | 0.650 |
Why?
|
Paraganglioma | 5 | 2022 | 143 | 0.640 |
Why?
|
Germ-Line Mutation | 11 | 2025 | 1885 | 0.600 |
Why?
|
Receptor, IGF Type 1 | 4 | 2019 | 384 | 0.600 |
Why?
|
Piperazines | 5 | 2024 | 2548 | 0.570 |
Why?
|
Clinical Trials as Topic | 10 | 2024 | 8048 | 0.570 |
Why?
|
Central Nervous System Neoplasms | 2 | 2023 | 928 | 0.570 |
Why?
|
Genomics | 16 | 2024 | 5924 | 0.560 |
Why?
|
Doxorubicin | 7 | 2023 | 2229 | 0.520 |
Why?
|
Child, Preschool | 43 | 2025 | 42606 | 0.520 |
Why?
|
Information Dissemination | 1 | 2024 | 1142 | 0.510 |
Why?
|
Proto-Oncogene Proteins | 4 | 2022 | 4522 | 0.510 |
Why?
|
Soft Tissue Neoplasms | 5 | 2023 | 1162 | 0.500 |
Why?
|
Pediatrics | 5 | 2020 | 3621 | 0.470 |
Why?
|
Ifosfamide | 5 | 2024 | 233 | 0.450 |
Why?
|
Mutation | 22 | 2024 | 30211 | 0.450 |
Why?
|
Gene Fusion | 3 | 2022 | 356 | 0.450 |
Why?
|
Marketing of Health Services | 1 | 2015 | 151 | 0.450 |
Why?
|
Adrenal Gland Neoplasms | 4 | 2022 | 733 | 0.440 |
Why?
|
Protein Kinase Inhibitors | 10 | 2023 | 5693 | 0.430 |
Why?
|
Cyclin-Dependent Kinase 4 | 4 | 2024 | 562 | 0.420 |
Why?
|
Humans | 142 | 2025 | 767040 | 0.420 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2016 | 678 | 0.410 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2024 | 2061 | 0.390 |
Why?
|
Pheochromocytoma | 3 | 2022 | 328 | 0.390 |
Why?
|
Etoposide | 5 | 2024 | 639 | 0.390 |
Why?
|
Sarcoma, Clear Cell | 2 | 2023 | 72 | 0.390 |
Why?
|
Immunoconjugates | 1 | 2019 | 975 | 0.380 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 939 | 0.360 |
Why?
|
Young Adult | 38 | 2024 | 59980 | 0.350 |
Why?
|
Cell Respiration | 1 | 2010 | 201 | 0.340 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 2902 | 0.340 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2024 | 352 | 0.340 |
Why?
|
Infant | 25 | 2024 | 36485 | 0.330 |
Why?
|
Gene Amplification | 3 | 2023 | 1088 | 0.330 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 4114 | 0.330 |
Why?
|
Vincristine | 5 | 2024 | 1040 | 0.330 |
Why?
|
Pyrimidines | 3 | 2024 | 3044 | 0.330 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13491 | 0.310 |
Why?
|
Genetic Predisposition to Disease | 8 | 2025 | 18063 | 0.300 |
Why?
|
Prognosis | 19 | 2023 | 29963 | 0.300 |
Why?
|
Tissue Banks | 3 | 2020 | 183 | 0.290 |
Why?
|
Amyloid Precursor Protein Secretases | 2 | 2022 | 616 | 0.280 |
Why?
|
Female | 64 | 2025 | 396660 | 0.280 |
Why?
|
Fibrosarcoma | 2 | 2020 | 313 | 0.280 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2024 | 2883 | 0.270 |
Why?
|
Patient Selection | 2 | 2017 | 4256 | 0.270 |
Why?
|
Feasibility Studies | 2 | 2021 | 5311 | 0.270 |
Why?
|
Proteins | 1 | 2021 | 6001 | 0.270 |
Why?
|
Male | 60 | 2025 | 364203 | 0.270 |
Why?
|
Electron Transport Complex II | 3 | 2019 | 53 | 0.270 |
Why?
|
National Cancer Institute (U.S.) | 6 | 2024 | 300 | 0.270 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4903 | 0.270 |
Why?
|
Pyrroles | 2 | 2024 | 1122 | 0.250 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9245 | 0.230 |
Why?
|
Genomic Structural Variation | 1 | 2025 | 80 | 0.230 |
Why?
|
Adult | 42 | 2025 | 223317 | 0.220 |
Why?
|
Disease-Free Survival | 5 | 2023 | 6844 | 0.220 |
Why?
|
Genetic Testing | 3 | 2017 | 3591 | 0.220 |
Why?
|
Rare Diseases | 2 | 2021 | 630 | 0.220 |
Why?
|
Busulfan | 1 | 2024 | 259 | 0.220 |
Why?
|
Myofibromatosis | 1 | 2023 | 27 | 0.210 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 2 | 2023 | 183 | 0.210 |
Why?
|
Melphalan | 1 | 2024 | 421 | 0.210 |
Why?
|
Internet | 1 | 2015 | 3114 | 0.200 |
Why?
|
Genome, Human | 2 | 2017 | 4441 | 0.200 |
Why?
|
BRCA1 Protein | 3 | 2024 | 1155 | 0.200 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1907 | 0.200 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.200 |
Why?
|
Cyclophosphamide | 3 | 2024 | 2227 | 0.200 |
Why?
|
Receptor Protein-Tyrosine Kinases | 4 | 2022 | 1621 | 0.190 |
Why?
|
BRCA2 Protein | 2 | 2024 | 802 | 0.190 |
Why?
|
Glomus Tumor | 1 | 2022 | 62 | 0.190 |
Why?
|
Transplantation, Autologous | 2 | 2024 | 2118 | 0.190 |
Why?
|
Phthalazines | 1 | 2024 | 397 | 0.190 |
Why?
|
Rhabdoid Tumor | 1 | 2023 | 211 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2022 | 80 | 0.190 |
Why?
|
Topotecan | 1 | 2021 | 131 | 0.190 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 531 | 0.190 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2021 | 43 | 0.190 |
Why?
|
Loss of Heterozygosity | 1 | 2023 | 663 | 0.180 |
Why?
|
Indenes | 1 | 2021 | 59 | 0.180 |
Why?
|
Indoles | 1 | 2009 | 1836 | 0.180 |
Why?
|
Polycythemia | 1 | 2021 | 124 | 0.180 |
Why?
|
Pelvic Neoplasms | 1 | 2022 | 249 | 0.180 |
Why?
|
Tandem Repeat Sequences | 1 | 2021 | 183 | 0.180 |
Why?
|
Tetrahydronaphthalenes | 1 | 2020 | 85 | 0.170 |
Why?
|
Infant, Newborn | 9 | 2024 | 26396 | 0.170 |
Why?
|
Biomedical Research | 3 | 2021 | 3464 | 0.170 |
Why?
|
Sequence Analysis, RNA | 4 | 2021 | 2040 | 0.170 |
Why?
|
Brain Neoplasms | 4 | 2023 | 9108 | 0.170 |
Why?
|
Treatment Outcome | 13 | 2024 | 65295 | 0.170 |
Why?
|
DEAD-box RNA Helicases | 2 | 2020 | 385 | 0.170 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.170 |
Why?
|
Myofibroma | 1 | 2019 | 45 | 0.160 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2599 | 0.160 |
Why?
|
Quinolines | 1 | 2024 | 770 | 0.160 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 2017 | 286 | 0.160 |
Why?
|
Nomograms | 1 | 2020 | 236 | 0.160 |
Why?
|
Benzamides | 3 | 2023 | 1376 | 0.160 |
Why?
|
Valine | 1 | 2020 | 410 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 115 | 0.150 |
Why?
|
Kidney Neoplasms | 3 | 2021 | 4282 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2020 | 228 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2020 | 8628 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2019 | 5332 | 0.150 |
Why?
|
Ribonuclease III | 1 | 2020 | 271 | 0.150 |
Why?
|
Dystrophin | 1 | 2019 | 283 | 0.150 |
Why?
|
Epigenomics | 3 | 2019 | 959 | 0.150 |
Why?
|
Nephroma, Mesoblastic | 1 | 2017 | 25 | 0.150 |
Why?
|
Neoplasm Metastasis | 6 | 2019 | 4892 | 0.150 |
Why?
|
Parotid Neoplasms | 1 | 2019 | 158 | 0.150 |
Why?
|
Resource Allocation | 1 | 2020 | 354 | 0.150 |
Why?
|
Legislation, Drug | 1 | 2020 | 216 | 0.150 |
Why?
|
DNA Repair | 2 | 2024 | 2050 | 0.150 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2019 | 2952 | 0.140 |
Why?
|
Glioma | 2 | 2022 | 3502 | 0.140 |
Why?
|
Retrospective Studies | 17 | 2024 | 81659 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 547 | 0.140 |
Why?
|
Microtubule-Associated Proteins | 2 | 2022 | 1074 | 0.140 |
Why?
|
Benzimidazoles | 1 | 2022 | 862 | 0.140 |
Why?
|
Informed Consent | 1 | 2023 | 1010 | 0.130 |
Why?
|
Neuroblastoma | 1 | 2025 | 1266 | 0.130 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2017 | 117 | 0.130 |
Why?
|
von Hippel-Lindau Disease | 1 | 2017 | 154 | 0.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2058 | 0.130 |
Why?
|
Karyopherins | 1 | 2016 | 134 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 343 | 0.130 |
Why?
|
Specimen Handling | 1 | 2020 | 706 | 0.130 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1144 | 0.120 |
Why?
|
SEER Program | 1 | 2020 | 1444 | 0.120 |
Why?
|
Survival Rate | 5 | 2019 | 12823 | 0.120 |
Why?
|
Genomic Imprinting | 1 | 2017 | 326 | 0.120 |
Why?
|
Pelvic Bones | 1 | 2017 | 274 | 0.120 |
Why?
|
Disease Models, Animal | 2 | 2014 | 18330 | 0.120 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2019 | 699 | 0.120 |
Why?
|
United States Food and Drug Administration | 3 | 2022 | 1672 | 0.120 |
Why?
|
RNA, Neoplasm | 1 | 2017 | 748 | 0.120 |
Why?
|
Pyridines | 2 | 2024 | 2890 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1502 | 0.110 |
Why?
|
Pyrazines | 1 | 2019 | 1204 | 0.110 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2024 | 5716 | 0.110 |
Why?
|
Imidazoles | 1 | 2019 | 1169 | 0.110 |
Why?
|
United States | 15 | 2024 | 72971 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 592 | 0.110 |
Why?
|
Cell Line, Tumor | 7 | 2022 | 17097 | 0.110 |
Why?
|
Databases, Factual | 3 | 2023 | 8068 | 0.110 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39317 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2021 | 2979 | 0.100 |
Why?
|
Age Factors | 5 | 2024 | 18401 | 0.100 |
Why?
|
Prospective Studies | 10 | 2024 | 54886 | 0.100 |
Why?
|
Leukemia | 1 | 2021 | 1518 | 0.100 |
Why?
|
Poverty | 1 | 2024 | 2719 | 0.100 |
Why?
|
Cisplatin | 3 | 2019 | 1656 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 1331 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1319 | 0.100 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 1027 | 0.100 |
Why?
|
Age of Onset | 1 | 2019 | 3344 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1444 | 0.100 |
Why?
|
Glucocorticoids | 1 | 2021 | 2163 | 0.100 |
Why?
|
DNA Copy Number Variations | 2 | 2019 | 2047 | 0.100 |
Why?
|
Methotrexate | 3 | 2019 | 1718 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 870 | 0.100 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 857 | 0.100 |
Why?
|
Gastrectomy | 1 | 2016 | 693 | 0.100 |
Why?
|
Combined Modality Therapy | 4 | 2022 | 8535 | 0.100 |
Why?
|
Cerebellar Neoplasms | 1 | 2016 | 590 | 0.090 |
Why?
|
Cell Survival | 1 | 2021 | 5750 | 0.090 |
Why?
|
Genetic Heterogeneity | 1 | 2014 | 735 | 0.090 |
Why?
|
Gene Dosage | 2 | 2017 | 1211 | 0.090 |
Why?
|
Medulloblastoma | 1 | 2016 | 682 | 0.090 |
Why?
|
Polyethylene Glycols | 1 | 2016 | 1188 | 0.090 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2013 | 393 | 0.090 |
Why?
|
Membrane Proteins | 3 | 2017 | 7868 | 0.090 |
Why?
|
Syndrome | 2 | 2021 | 3271 | 0.090 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3440 | 0.090 |
Why?
|
Antidotes | 1 | 2010 | 138 | 0.080 |
Why?
|
MicroRNAs | 2 | 2017 | 3792 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2021 | 2509 | 0.080 |
Why?
|
Biopsy | 4 | 2024 | 6777 | 0.080 |
Why?
|
DNA Damage | 3 | 2024 | 2469 | 0.080 |
Why?
|
Germ Cells | 2 | 2023 | 644 | 0.080 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2011 | 289 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2024 | 1244 | 0.080 |
Why?
|
Heart Neoplasms | 1 | 2012 | 374 | 0.080 |
Why?
|
Treatment Failure | 2 | 2017 | 2658 | 0.070 |
Why?
|
Mediastinal Neoplasms | 1 | 2011 | 403 | 0.070 |
Why?
|
Ecosystem | 2 | 2023 | 489 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2017 | 16036 | 0.070 |
Why?
|
Protein Subunits | 1 | 2010 | 940 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10748 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4539 | 0.070 |
Why?
|
Translocation, Genetic | 2 | 2023 | 1391 | 0.070 |
Why?
|
Survivors | 2 | 2023 | 2381 | 0.070 |
Why?
|
Disease Progression | 5 | 2021 | 13646 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12986 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2930 | 0.070 |
Why?
|
Oncogenes | 2 | 2022 | 1232 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2355 | 0.060 |
Why?
|
Neurotoxicity Syndromes | 1 | 2010 | 302 | 0.060 |
Why?
|
Mice, Nude | 3 | 2019 | 3618 | 0.060 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11063 | 0.060 |
Why?
|
Cyclin D | 1 | 2024 | 71 | 0.060 |
Why?
|
Chromosome Aberrations | 2 | 2025 | 1776 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5702 | 0.060 |
Why?
|
Immunotherapy | 2 | 2021 | 4745 | 0.060 |
Why?
|
Risk Assessment | 3 | 2020 | 24299 | 0.060 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2011 | 949 | 0.060 |
Why?
|
Forecasting | 1 | 2013 | 2936 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 2012 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5446 | 0.060 |
Why?
|
Computer Simulation | 1 | 2017 | 6260 | 0.050 |
Why?
|
Clinical Protocols | 2 | 2022 | 1443 | 0.050 |
Why?
|
Gene Expression Profiling | 5 | 2017 | 9532 | 0.050 |
Why?
|
Infertility | 1 | 2010 | 655 | 0.050 |
Why?
|
Blotting, Western | 1 | 2010 | 5022 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6360 | 0.050 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5794 | 0.050 |
Why?
|
Cyclic AMP Response Element Modulator | 1 | 2023 | 88 | 0.050 |
Why?
|
Vidarabine | 1 | 2024 | 337 | 0.050 |
Why?
|
Hearing Loss | 1 | 2010 | 785 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2016 | 3928 | 0.050 |
Why?
|
Normetanephrine | 1 | 2021 | 25 | 0.050 |
Why?
|
Lymphocyte Depletion | 1 | 2024 | 605 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1061 | 0.050 |
Why?
|
Dogs | 2 | 2019 | 3834 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10869 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2007 | 3587 | 0.050 |
Why?
|
3-Iodobenzylguanidine | 1 | 2022 | 114 | 0.050 |
Why?
|
Middle Aged | 14 | 2024 | 223233 | 0.050 |
Why?
|
Research Design | 2 | 2017 | 6210 | 0.050 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.050 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2023 | 257 | 0.050 |
Why?
|
Trismus | 1 | 2020 | 33 | 0.050 |
Why?
|
Sacrum | 1 | 2022 | 274 | 0.040 |
Why?
|
DNA Methylation | 4 | 2017 | 4426 | 0.040 |
Why?
|
Survival Analysis | 3 | 2018 | 10092 | 0.040 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 33 | 0.040 |
Why?
|
Signal Transduction | 5 | 2021 | 23621 | 0.040 |
Why?
|
Oncogene Proteins | 2 | 2017 | 715 | 0.040 |
Why?
|
Aminopyridines | 1 | 2024 | 578 | 0.040 |
Why?
|
RNA-Binding Protein EWS | 1 | 2021 | 211 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2022 | 428 | 0.040 |
Why?
|
Oncogene Fusion | 1 | 2020 | 84 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2023 | 11657 | 0.040 |
Why?
|
RNA | 2 | 2022 | 2715 | 0.040 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 6067 | 0.040 |
Why?
|
Phosphorylation | 1 | 2010 | 8310 | 0.040 |
Why?
|
Codon | 1 | 2021 | 599 | 0.040 |
Why?
|
Mice | 6 | 2022 | 81912 | 0.040 |
Why?
|
Cell Cycle | 2 | 2019 | 2927 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 635 | 0.040 |
Why?
|
Animals | 9 | 2022 | 168965 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 518 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2010 | 2099 | 0.040 |
Why?
|
RNA Interference | 2 | 2019 | 2829 | 0.040 |
Why?
|
Adrenal Glands | 1 | 2021 | 557 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3608 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10455 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 892 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 328 | 0.040 |
Why?
|
Workers' Compensation | 1 | 1999 | 150 | 0.040 |
Why?
|
Calcitonin | 1 | 2019 | 328 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 854 | 0.040 |
Why?
|
Endothelial Cells | 1 | 2011 | 3582 | 0.040 |
Why?
|
Carbazoles | 1 | 2019 | 230 | 0.040 |
Why?
|
Stem Cells | 1 | 2011 | 3535 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2022 | 1987 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12536 | 0.040 |
Why?
|
GTP-Binding Proteins | 1 | 2022 | 946 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 41718 | 0.040 |
Why?
|
Drug Labeling | 1 | 2020 | 251 | 0.040 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2017 | 69 | 0.040 |
Why?
|
American Cancer Society | 1 | 2017 | 69 | 0.040 |
Why?
|
Utah | 1 | 2017 | 130 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21178 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2024 | 1492 | 0.030 |
Why?
|
Heart Diseases | 1 | 2010 | 2817 | 0.030 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 178 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4780 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 313 | 0.030 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2017 | 194 | 0.030 |
Why?
|
Risk Factors | 5 | 2025 | 74886 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1614 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2017 | 303 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 474 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2017 | 252 | 0.030 |
Why?
|
Safety | 1 | 2020 | 1157 | 0.030 |
Why?
|
Aged | 8 | 2024 | 171319 | 0.030 |
Why?
|
Carpal Tunnel Syndrome | 1 | 1999 | 304 | 0.030 |
Why?
|
Exons | 1 | 2021 | 2391 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2511 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10254 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3207 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7435 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 615 | 0.030 |
Why?
|
Hydrazines | 1 | 2016 | 223 | 0.030 |
Why?
|
Drug Synergism | 1 | 2018 | 1759 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2017 | 751 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2019 | 1788 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2017 | 456 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 1761 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1326 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 842 | 0.030 |
Why?
|
Data Collection | 1 | 2023 | 3321 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 719 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2022 | 2028 | 0.030 |
Why?
|
Computational Biology | 2 | 2017 | 3567 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2016 | 793 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 742 | 0.030 |
Why?
|
Motivation | 1 | 2023 | 2021 | 0.030 |
Why?
|
Models, Biological | 2 | 2021 | 9464 | 0.030 |
Why?
|
Chromatin | 1 | 2025 | 2980 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 820 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2021 | 59548 | 0.030 |
Why?
|
Early Detection of Cancer | 2 | 2017 | 3236 | 0.030 |
Why?
|
Europe | 1 | 2019 | 3432 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1900 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2019 | 1147 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3599 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2702 | 0.020 |
Why?
|
Self Efficacy | 1 | 2016 | 643 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2800 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1741 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12414 | 0.020 |
Why?
|
Regression Analysis | 1 | 2020 | 6331 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 1697 | 0.020 |
Why?
|
Piperidines | 1 | 2019 | 1667 | 0.020 |
Why?
|
Sex Factors | 1 | 2025 | 10622 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 903 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13485 | 0.020 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2012 | 193 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 2900 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2015 | 1058 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20169 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3618 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3611 | 0.020 |
Why?
|
Genomic Instability | 1 | 2013 | 716 | 0.020 |
Why?
|
Acetylation | 1 | 2011 | 1055 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 483 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40154 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6893 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3828 | 0.020 |
Why?
|
Health Policy | 1 | 2020 | 2698 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 3552 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9612 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1604 | 0.020 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 627 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15851 | 0.020 |
Why?
|
Carcinoma | 1 | 2017 | 2326 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6513 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2721 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2016 | 2337 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2011 | 777 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6550 | 0.020 |
Why?
|
Bone Marrow | 1 | 2016 | 2926 | 0.020 |
Why?
|
Proteomics | 1 | 2019 | 3913 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5796 | 0.010 |
Why?
|
Research | 1 | 2012 | 1977 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9360 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12158 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7063 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8504 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7611 | 0.010 |
Why?
|
Transfection | 1 | 2011 | 5753 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 2391 | 0.010 |
Why?
|
Parents | 1 | 2016 | 3594 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3427 | 0.010 |
Why?
|
Histones | 1 | 2011 | 2597 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2011 | 5891 | 0.010 |
Why?
|
Antigens, CD | 1 | 2011 | 4032 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36582 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20741 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 12793 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10393 | 0.010 |
Why?
|
New York | 1 | 1999 | 879 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 13035 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 4049 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26325 | 0.010 |
Why?
|
Insurance Claim Review | 1 | 1999 | 744 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22254 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 1999 | 7848 | 0.000 |
Why?
|
Logistic Models | 1 | 1999 | 13284 | 0.000 |
Why?
|
Health Services Accessibility | 1 | 1999 | 5519 | 0.000 |
Why?
|